Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves Differin Epiduo Acne Gel Switch to OTC
    FDA Approves Differin Epiduo Acne Gel Switch to OTC

    22 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260522074280/en/Galderma-Receives-U.S.-FDA-Approval-for-Differin-Epiduo-Acne-Gel-Prescription-to-OTC-Switch

    BUSINESSWIRE
    22 May 2026
    Share Share
    Galderma ’s Differin Epiduo Acne Gel Receives Approval in US
    Galderma ’s Differin Epiduo Acne Gel Receives Approval in US

    22 May 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220736

    FDA
    22 May 2026
    Share Share
    Health Canada Approves CABTREO Triple Combo For Acne Vulgaris
    Health Canada Approves CABTREO Triple Combo For Acne Vulgaris

    11 Sep 2024

    // ACCESSWIRE

    https://www.accesswire.com/915793/health-canada-approves-prcabtreotm-clindamycin-phosphate-adapalene-and-benzoyl-peroxide-triple-combination-topical-treatment-for-acne-vulgaris-in-patients-12-years-of-age-and-older

    ACCESSWIRE
    11 Sep 2024
    Share Share
    Enforcement Report - Week of February 28, 2024
    Enforcement Report - Week of February 28, 2024

    28 Feb 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-28-2024-59068.pdf

    FDA
    28 Feb 2024
    Share Share
    FDA Approves Cabtreo(TM) Topical Gel
    FDA Approves Cabtreo(TM) Topical Gel

    20 Oct 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=795118&lang=en

    ACCESSWIRE
    20 Oct 2023
    Share Share
    Alembic Pharma subsidiary, Aleor Dermaceuticals gets USFDA nod for acne gel
    Alembic Pharma subsidiary, Aleor Dermaceuticals gets USFDA nod for acne gel

    08 Aug 2022

    // ET HEALTH

    https://health.economictimes.indiatimes.com/news/pharma/alembic-pharma-subsidiary-aleor-dermaceuticals-gets-usfda-nod-for-acne-gel/93423857

    ET HEALTH
    08 Aug 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.